CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.25B, above the global median of $1.15B
- FinancialsHigh structural barrier to entry
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
1.25BUSDvs all stocks (USD)
Revenue (TTM)
360.78MUSDvs all stocks (USD)
Profit Margin
-6.63%vs Biotechnology peers
Beta
1.09xvs all stocks
52-Week Change
5.50%vs all stocks
Market Capitalization
1.25BUSDvs all stocks (USD)
Enterprise Value
1.55BUSDvs all stocks (USD)
Forward P/E
20.94xvs Biotechnology peers
Price to Sales (TTM)
3.45xvs Biotechnology peers
Enterprise to Revenue
4.28xvs Biotechnology peers
Enterprise to EBITDA
43.75xvs Biotechnology peers
Gross Margin
80.62%vs Biotechnology peers
Profit Margin
-6.63%vs Biotechnology peers
Operating Margin
-3.31%vs Biotechnology peers
Return on Assets (TTM)
2.03%vs Biotechnology peers
Revenue (TTM)
360.78MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.31USDUpdated Jul 19, 2026Quarterly Revenue Growth
15.10%vs Biotechnology peers
Gross Profit (TTM)
272.87MUSDvs all stocks (USD)
EBITDA (TTM)
65.67MUSDvs all stocks (USD)
Net Income (TTM)
-23.91MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
15.08%vs Biotechnology peers
Operating Cash Flow (TTM)
19.27MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
47.00MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
348.97MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
87.96MUSDFY2025 · Dec 31, 2025Gross Profit
261.01MUSDFY2025 · Dec 31, 2025Operating Income
46.55MUSDvs all stocks (USD)
Pre-tax Income
1.41MUSDFY2025 · Dec 31, 2025Income Tax Expense
-4.46MUSDFY2025 · Dec 31, 2025Net Income
5.86MUSDFY2025 · Dec 31, 2025EBIT
39.23MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
65.67MUSDFY2025 · Dec 31, 2025Research & Development
66.35MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
144.13MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
8.05MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
37.82MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.0200USDFY2025 · Dec 31, 2025EPS (Diluted)
0.0200USDFY2025 · Dec 31, 2025Basic Shares Outstanding
305.64MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
305.64MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
5.86MUSDFY2025 · Dec 31, 2025Operating Cash Flow
8.09MUSDFY2025 · Dec 31, 2025Free Cash Flow
3.53MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
75.63MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.71MUSDFY2025 · Dec 31, 2025Interest Paid
14.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
5.86MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
12.28MUSDFY2025 · Dec 31, 2025Stock-based Compensation
24.20MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.89MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-4.76MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-16.71MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.66MUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.57MUSDFY2025 · Dec 31, 2025Net Acquisitions
-347.74MUSDFY2025 · Dec 31, 2025Purchase of Investments
-157.80MUSDFY2025 · Dec 31, 2025Sale of Investments
215.31MUSDFY2025 · Dec 31, 2025Other Investing Activity
-10.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-304.80MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
325.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-11.89MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
313.11MUSDFY2025 · Dec 31, 2025Shares Outstanding
308.91MSharesUpdated Jul 19, 2026Float Shares
303.07MSharesUpdated Jul 19, 2026Shares Short
26.19MSharesUpdated Jul 19, 2026Short Ratio
4.97daysvs all stocks
Short % of Shares Outstanding
8.59%vs all stocks
% Held by Insiders
1.55%vs all stocks
% Held by Institutions
59.25%vs all stocks
Total Cash (MRQ)
133.86MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4330USDUpdated Jul 19, 2026Total Debt (MRQ)
434.15MUSDvs all stocks (USD)
Current Ratio (MRQ)
1.87xvs Biotechnology peers
Book Value per Share (MRQ)
-0.1920USDUpdated Jul 19, 2026Total Assets
792.18MUSDvs all stocks (USD)
Total Current Assets
291.58MUSDFY2025 · Dec 31, 2025Total Liabilities
843.20MUSDFY2025 · Dec 31, 2025Total Non-current Assets
500.60MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
672.17MUSDFY2025 · Dec 31, 2025Total Current Liabilities
171.03MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
74.88MUSDFY2025 · Dec 31, 2025Other Short-term Investments
96.46MUSDFY2025 · Dec 31, 2025Accounts Receivable
38.37MUSDFY2025 · Dec 31, 2025Inventory
35.31MUSDFY2025 · Dec 31, 2025Accounts Payable
9.03MUSDFY2025 · Dec 31, 2025Short-term Debt
38.39MUSDFY2025 · Dec 31, 2025Deferred Revenue
15.33MUSDFY2025 · Dec 31, 2025Other Current Liabilities
51.29MUSDFY2025 · Dec 31, 2025Long-term Debt
329.05MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
303.15MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.08MUSDFY2025 · Dec 31, 2025Retained Earnings
-3.20BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-51.02MUSDvs all stocks (USD)
52-Week Low
2.23USDUpdated Jul 19, 202652-Week High
6.51USDUpdated Jul 19, 202652-Week Change
5.50%vs all stocks
Beta
1.09xvs all stocks
50-Day MA
3.72USDUpdated Jul 19, 2026200-Day MA
4.40USDUpdated Jul 19, 2026Avg 10-Day Volume
4.31MSharesUpdated Jul 19, 2026Avg 30-Day Volume
4.91MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.0700USDUpdated Jul 19, 2026Other Income / Expense
-15.17MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Depreciation-Heavy Reported Profit
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
Where is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.15Receivables vs revenue divergence: 3.74
High gross margins eroded by operating costsNotable
Gross Margin: 0.81Profit Margin: -0.07
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.73
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.25B, above the global median of $1.15BNotable
Market cap (USD): 1,245,069,168Global Median: 1,146,734,693.424
Levered free cash flow is $47M, above the global median of $16.24MNotable
Levered free cash flow (USD): 47,002,500Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Hubei Hongyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xianju Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Corvus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sequent Scientific Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Viyash Scientific Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sonoscape Medical Corp.
Tier 1ProductionApproval-Gated PipelineRule
Kissei Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Gray Television, Inc.
2 interpretationsDepreciation-Heavy Reported ProfitWithin or Near the Altman Distress Zone
Liberty Latin America Ltd.
2 interpretationsDepreciation-Heavy Reported ProfitWithin or Near the Altman Distress Zone
Kyndryl Holdings Inc.
2 interpretationsDepreciation-Heavy Reported ProfitWithin or Near the Altman Distress Zone